{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-213726","form_type":"8-K","ticker":"LNTH","cik":"0001521036","company_name":"Lantheus Holdings, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.358815+00:00","generated_at":"2026-05-31T06:14:13.660751+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Lantheus appoints Julie Eastland to Board of Directors, effective Sept 3, 2024","bullets":["Board size increased to ten directors; Eastland is a Class I director and Audit Committee member.","Eastland qualifies as independent under Nasdaq rules; compensation includes $60K/yr cash plus prorated equity grant valued at $266,666.67.","She brings biotech and finance experience, most recently CEO of Harpoon Therapeutics until its acquisition by Merck in March 2024.","No arrangements or family relationships with existing directors or officers; no disclosable transactions."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-213726","json":"https://secwatch.observer/filing/0001193125-24-213726.json","markdown":"https://secwatch.observer/filing/0001193125-24-213726.md","text":"https://secwatch.observer/filing/0001193125-24-213726.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/0001193125-24-213726-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/d886086d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:14:13.660751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e12a8b75d","claim":"Julie Eastland was appointed as Director at Lantheus Holdings, Inc..","evidence_excerpt":"On September 3, 2024, the board of directors of Lantheus Holdings, Inc. (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee, appointed Julie Eastland, an experienced biotechnology and financial executive, to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1521036/000119312524213726/0001193125-24-213726-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}